SHANGHAI – Innovent Biologics Inc., of Suzhou, has acquired the global rights for a preclinical indoleamine 2,3-dioxygenase (IDO) inhibitor discovered by the Shanghai Institute of Organic Chemistry. By adding an IDO candidate to its immuno-oncology pipeline, Innovent aims to increase the effectiveness of its PD-1 candidate currently in phase III studies in partnership with Eli Lilly and Co.. of Indianapolis.